JOAQUÍN
DÍAZ MEDIAVILLA
Investigador hasta 2014
Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer (9)
2016
-
Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia
Leukemia Research, Vol. 40, pp. 1-9
2013
2012
2010
-
BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)
Annals of Hematology, Vol. 89, Núm. 5, pp. 453-458
-
Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients
Haematologica, Vol. 95, Núm. 5, pp. 745-751
2009
-
High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics
Leukemia Research, Vol. 33, Núm. 12, pp. 1706-1709